Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation

Using its UNIarray protein array platform, the company plans to focus on the development of serum-based protein biomarker tests for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.